Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan

Ming-Chung Kuo, Chien-Chin Lin, Hsuan-Yu Lin, Jyh-Pyng Gau, Ming-Chung Wang, Ming-Chih Chang, Tsung-Chih Chen, Shih-Peng Yeh, Yeu-Chin Chen, Sr., Cih-En Huang, I-Ju Chiang, Chu-Han Chung, Yee-Ming Lee, Fan-Chen Ku, Cheng-Shyong Chang

Blood (2022) 140 (Supplement 1): 9709–9710.

https://doi.org/10.1182/blood-2022-156146

Published: 2022

Journal Articles

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan Sangerman, Stef Meers, Vinod A. Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Jiaying Lyu, Pedro Marques Ramos, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 2063–2065.

https://doi.org/10.1182/blood-2022-158612

Published: 2022

Journal Articles

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Matthew J. Matasar, Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li, Eduardo Yañez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Barrett H Childs, Yuankai Shi, Pier Luigi Luigi Zinzani

Blood (2021) 138 (Supplement 1): 3538.

https://doi.org/10.1182/blood-2021-150873

Published: 2021

Journal Articles

A Meta-Analysis of Pivotal Pralatrexate Studies in Relapsed/Refractory Mature T-Cell Lymphoma (r/r TCL)

Owen A. O'Connor, Bor-Sheng Ko, Ming-Chung Wang, Dai Maruyama, Yuqin Song, Ee-Min Yeoh, Kensei Tobinai

Blood (2021) 138 (Supplement 1): 2450.

https://doi.org/10.1182/blood-2021-145580

Published: 2021

Journal Articles

Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan

Hsin-An Hou, Chien-Chin Lin, MD, Ming-Chung Kuo, MD, Shyuann-Yuh Lin, MD, Jyh-Pyng Gau, MD, Ming-Chung Wang, MD, Ming-Chih Chang, MD, Tsung-Chih Chen, MD, Su-Peng Yeh, MD, Yeu-Chin Chen, MD, Cih-En Huang, MD, Chieh-Wen Chen, MD, Yee-Ming Lee, PhD, Fan-Chen Ku, MD, Lee-Yung Shih, MD

Blood (2019) 134 (Supplement_1): 5374.

https://doi.org/10.1182/blood-2019-129645

Published: 2019

Journal Articles

Risk Factors Associated with Earlier Relapse and Death and Treatment Response in Patients with Follicular Lymphoma in Taiwan

Sung-Nan Pei, MD, Kuan-Chih Huang, Ming-Chung Wang, MD, Ching-Yuan Kuo, Ming-Chun Ma, MD, Chun-Kai Liao, MD, Lee Anne Rothwell, PhD, Hong Qiu, MD PhD, Yanfang Liu, MD MPH

Blood (2018) 132 (Supplement 1): 5338.

https://doi.org/10.1182/blood-2018-99-112347

Published: 2018

Journal Articles

Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

Yi-Jiun Su, MD, Ming-Chung Kuo, MD, Chieh-Lin Teng, MD, Tsai-Yun Chen, MD, Ming-Chun Ma, MD, Pei-Ching Hsiao, MD, Ming-Chung Wang, MD, Tung-Huei Lin, MS, Wen-Li Hwang, MD, Chih-Cheng Chen, MD, Youngsen Yang, MD, Sung-Nan Pei, MD, Yen-Min Huang, MD, Sin-Syue Li, MD, Ming-Yang Lee, MD, Hung-I Cheng, MD, Lee-Yung Shih, MD

Blood (2017) 130 (Supplement 1): 1603.

https://doi.org/10.1182/blood.V130.Suppl_1.1603.1603

Published: 2017

Journal Articles

High Titers of Hepatitis B Surface Antibodies Indicating Low Risk of Hepatitis B Virus-Related Hepatitis in Lymphoma Patients Treated with Rituximab-Based Chemotherapy

Sung-Nan Pei, MD, Ming-Chung Wang, MD, Ming-Chung Ma, MD, Ching-Yuan Kuo, MD, Chien-Hung Chen, Po-Nan Wang, MD

Blood (2015) 126 (23): 3869.

https://doi.org/10.1182/blood.V126.23.3869.3869

Published: 2015

Journal Articles

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Ming-Chung Kuo, MD, Tsai-Yun Chen, MD, Ming-Chung Wang, MD, Youngsen Yang, MD, Su-Peng Yeh, MD, Cheng-Shyong Chang, MD, Yii-Jenq Lan, MD, Chih-Cheng Chen, MD, Yu-Chieh Su, MD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, MD, Li-Yuan Bai, MD, Wen-Li Hwang, MD, Lee-Yung Shih, MD

Blood (2014) 124 (21): 4544.

https://doi.org/10.1182/blood.V124.21.4544.4544

Published: 2014

Journal Articles

Pegylated Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory and/or Elder Acute Myeloid Leukemia: The Preliminary Result of Phase II Trial

Hui-Jen Tsai, MD PhD, Ming-Chung Wang, MD, Sheng-Fung Lin, MD, Ya-Ping Chen, MD PhD, Hui-Hwa Hsiao, MD PhD, Ching-Yuan Kuo, MD, Li-Tzong Chen, MD PhD, Tsai-Yun Chen, MD

Blood (2014) 124 (21): 984.

https://doi.org/10.1182/blood.V124.21.984.984

Published: 2014

Journal Articles

A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF)

Chul Won Jung, MD, PhD, Lee-Yung Shih, MD, Zhijian Xiao, MD, Jie Jin, MD, Hsin-An Hou, MD, Xin Du, MD, Ming-Chung Wang, MD, Seonyang Park, MD, PhD, Ki-Seong Eom, MD, PhD, Kenji Oritani, Shinichiro Okamoto, MD, PhD, Tetsuzo Tauchi, MD, Jin Seok Kim, MD, Daobin Zhou, MD, Andres Sirulnik, MD, PhD, Wanda Ruiz, PhD, Taro Amagasaki, PhD, Kazuo Ito, Koichi Akashi, MD, PhD

Blood (2013) 122 (21): 4086.

https://doi.org/10.1182/blood.V122.21.4086.4086

Published: 2013

Journal Articles

Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd

Richard A. Larson, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD, PhD, Gianantonio Rosti, MD, Jose L. Lopez, MD, Leif Stenke, MD, PhD, Hirohisa Nakamae, M.D., Ph.D., Stuart L. Goldberg, M.D., Ming-Chung Wang, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Christine-Elke Ortmann, Timothy P. Hughes, MD, MBBS, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 2291.

https://doi.org/10.1182/blood.V116.21.2291.2291

Published: 2010

NARROW

Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

A Meta-Analysis of Pivotal Pralatrexate Studies in Relapsed/Refractory Mature T-Cell Lymphoma (r/r TCL)

Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan

Risk Factors Associated with Earlier Relapse and Death and Treatment Response in Patients with Follicular Lymphoma in Taiwan

Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

High Titers of Hepatitis B Surface Antibodies Indicating Low Risk of Hepatitis B Virus-Related Hepatitis in Lymphoma Patients Treated with Rituximab-Based Chemotherapy

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Pegylated Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory and/or Elder Acute Myeloid Leukemia: The Preliminary Result of Phase II Trial

A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF)

Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only